[go: up one dir, main page]

ES2160570T3 - Mutantes de neumolisina y vacunas de neumococos fabricadas a partir de los mismos. - Google Patents

Mutantes de neumolisina y vacunas de neumococos fabricadas a partir de los mismos.

Info

Publication number
ES2160570T3
ES2160570T3 ES90900035T ES90900035T ES2160570T3 ES 2160570 T3 ES2160570 T3 ES 2160570T3 ES 90900035 T ES90900035 T ES 90900035T ES 90900035 T ES90900035 T ES 90900035T ES 2160570 T3 ES2160570 T3 ES 2160570T3
Authority
ES
Spain
Prior art keywords
mutants
vaccines
pneumococes
pneumolisin
manufactured
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90900035T
Other languages
English (en)
Inventor
James Cleland Paton
Graham John Boulnois
Peter William Andrew
Timothy John Mitchell
John Arthur Walker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nederlanden Staat
Original Assignee
Nederlanden Staat
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nederlanden Staat filed Critical Nederlanden Staat
Application granted granted Critical
Publication of ES2160570T3 publication Critical patent/ES2160570T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C07K14/3156—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci from Streptococcus pneumoniae (Pneumococcus)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Manufacturing Of Steel Electrode Plates (AREA)
  • Current-Collector Devices For Electrically Propelled Vehicles (AREA)
  • Exchange Systems With Centralized Control (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

SE HAN OBTENIDO MUTANTES DE NEUMOLISINA QUE SON NO-TOXICOS DEBIDO A SUSTITUCIONES DE AMINOACIDO. ESTOS MUTANTES CONSIGUEN UNA RESPUESTA INMUNE EN ANIMALES QUE ES REACTIVA A NEUMOLISINA DE TIPO SALVAJE. LA INVENCION TAMBIEN ABARCA VACUNAS PARA HUMANOS BASADOS EN ESOS MUTANTES, INCLUYENDO VACUNAS QUE CONTIENEN CONJUGADOS CON POLISACARIDOS CAPSULARES DE NEUMOCOCOS.
ES90900035T 1988-12-16 1989-12-15 Mutantes de neumolisina y vacunas de neumococos fabricadas a partir de los mismos. Expired - Lifetime ES2160570T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AUPJ198988 1988-12-16

Publications (1)

Publication Number Publication Date
ES2160570T3 true ES2160570T3 (es) 2001-11-16

Family

ID=3773589

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90900035T Expired - Lifetime ES2160570T3 (es) 1988-12-16 1989-12-15 Mutantes de neumolisina y vacunas de neumococos fabricadas a partir de los mismos.

Country Status (15)

Country Link
EP (1) EP0449856B1 (es)
JP (1) JP3237842B2 (es)
AT (1) ATE205534T1 (es)
AU (1) AU626961B2 (es)
BG (1) BG51358A3 (es)
CA (1) CA2005704C (es)
DE (1) DE68929323T2 (es)
DK (1) DK173629B1 (es)
ES (1) ES2160570T3 (es)
FI (1) FI103122B1 (es)
HU (1) HUT58804A (es)
MC (1) MC2178A1 (es)
NO (1) NO304317B1 (es)
RU (1) RU2121481C1 (es)
WO (1) WO1990006951A1 (es)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6716432B1 (en) * 1988-12-16 2004-04-06 James Cleland Paton Pneumolysin mutants and pneumococcal vaccines made therefrom
CA2059693C (en) * 1991-01-28 2003-08-19 Peter J. Kniskern Polysaccharide antigens from streptococcus pneumoniae
US5391712A (en) * 1991-08-30 1995-02-21 Beckman Instruments, Inc. Non-hemolytic streptolysin O variants
US5928900A (en) * 1993-09-01 1999-07-27 The Rockefeller University Bacterial exported proteins and acellular vaccines based thereon
WO1995016711A1 (es) * 1993-12-17 1995-06-22 Universidad De Oviedo Anticuerpos contra la neumolisina y sus aplicaciones
US8791237B2 (en) 1994-11-08 2014-07-29 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of non-hodgkins lymphoma
HUP0002475A3 (en) * 1997-07-21 2002-01-28 Baxter Healthcare S A Wallisel Modified immunogenic pneumolysin compositions as vaccines
GB9906437D0 (en) * 1999-03-19 1999-05-12 Smithkline Beecham Biolog Vaccine
HU229968B1 (hu) * 1999-03-19 2015-03-30 Smithkline Beecham Biologicals S.A Sztreptokokkusz oltóanyag
GB9918319D0 (en) 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
GB0022742D0 (en) * 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
MXPA03003690A (es) 2000-10-27 2004-05-05 Chiron Spa Acidos nucleicos y proteinas de los grupos a y b de estreptococos.
GB0109297D0 (en) 2001-04-12 2001-05-30 Glaxosmithkline Biolog Sa Vaccine
EP1524990A2 (en) 2002-08-02 2005-04-27 GlaxoSmithKline Biologicals S.A. Vaccine composition comprising lipooligosaccharide with reduced phase variability
TWI332843B (en) 2002-11-01 2010-11-11 Glaxosmithkline Biolog Sa Immunogenic composition
KR20050086427A (ko) 2002-11-07 2005-08-30 시너지 아메리카 인코포레이티드 폐렴균의 감염 치료 또는 예방용 조성물 및 방법
US8084235B2 (en) * 2003-03-13 2011-12-27 Glaxosmithkline Biologicals S.A. Purification process for bacterial cytolysin
EP1648500B1 (en) 2003-07-31 2014-07-09 Novartis Vaccines and Diagnostics, Inc. Immunogenic compositions for streptococcus pyogenes
US8945589B2 (en) 2003-09-15 2015-02-03 Novartis Vaccines And Diagnostics, Srl Immunogenic compositions for Streptococcus agalactiae
EP1667712B1 (en) 2003-10-02 2010-07-21 GlaxoSmithKline Biologicals S.A. B. pertussis antigens and use thereof in vaccination
US20060257421A1 (en) * 2004-02-13 2006-11-16 Martina Ochs Pneumolysin derivatives
WO2005108419A1 (en) * 2004-05-07 2005-11-17 Lea-Ann Kirkham Mutant cholesterol-binding cytolysin proteins
GB0410220D0 (en) * 2004-05-07 2004-06-09 Kirkham Lea Ann Mutant pneumolysin proteins
EP2612679A1 (en) 2004-07-29 2013-07-10 Novartis Vaccines and Diagnostics, Inc. Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
GB0421083D0 (en) * 2004-09-22 2004-10-27 Glaxosmithkline Biolog Sa Purification process
JP2008544949A (ja) 2004-10-08 2008-12-11 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 化膿性レンサ球菌のための免疫激性組成物および治療用組成物
GB0505996D0 (en) 2005-03-23 2005-04-27 Glaxosmithkline Biolog Sa Fermentation process
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
TW201350129A (zh) 2005-12-22 2013-12-16 Glaxosmithkline Biolog Sa 包含莢膜醣結合物之肺炎鏈球菌免疫原組合物、包含其之疫苗及套組及其用途
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
NZ569417A (en) 2006-01-17 2012-04-27 Arne Forsgren A novel surface exposed haemophilus influenzae protein (protein E; pE)
ES2822058T3 (es) 2006-09-26 2021-04-28 Infectious Disease Res Inst Composición de vacuna que contiene un adyuvante sintético
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
MX2009003325A (es) 2006-10-12 2009-04-09 Glaxosmithkline Biolog Sa Vacuna que comprende un adyuvante de emulsion de aceite en agua.
SI2086582T1 (sl) 2006-10-12 2013-02-28 Glaxosmithkline Biologicals S.A. Cepivo, ki obsega emulzijo olja v vodi kot adjuvans
CA2896131C (en) 2007-03-02 2020-04-07 Glaxosmithkline Biologicals S.A. Novel method and compositions
US9717788B2 (en) 2007-03-02 2017-08-01 Glaxosmithkline Biologicals Sa Method of inducing an immune response against HIV employing HIV immunogens, adenoviral vectors encoding said immunogens, and adjuvant
EP2386567B1 (en) * 2007-04-13 2014-10-29 The Board Of Regents Of The University Of Oklahoma Mutants of cholesterol-dependent cytolysins and uses thereof
BRPI0813307C1 (pt) * 2007-06-26 2021-05-25 Glaxosmithkline Biologicals Sa composição imunogênica, vacina, e, processo para fabricar a vacina
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
WO2009034473A2 (en) 2007-09-12 2009-03-19 Novartis Ag Gas57 mutant antigens and gas57 antibodies
JP5656642B2 (ja) 2007-12-21 2015-01-21 ノバルティス アーゲー ストレプトリシンｏの変異体形態
WO2009127676A1 (en) 2008-04-16 2009-10-22 Glaxosmithkline Biologicals S.A. Vaccine
GB0815872D0 (en) 2008-09-01 2008-10-08 Pasteur Institut Novel method and compositions
CN102712680B (zh) * 2008-12-24 2016-06-22 荷兰王国卫生福利和运动部国家公共卫生和环境研究所 修饰的肺炎链球菌溶血素(ply)多肽
AU2010227220B2 (en) 2009-03-24 2014-11-13 Glaxosmithkline Biologicals S.A. Combinations of meningococcal factor H binding protein and pneumococcal saccharide conjugates
PT2437753T (pt) 2009-06-05 2016-11-23 Infectious Disease Res Inst Adjuvantes lipídicos de glucopiranosilo sintéticos e composições de vacina contendo os mesmos
KR20120081587A (ko) 2009-09-10 2012-07-19 노파르티스 아게 기도 질병에 대한 조합 백신
CN102939105B (zh) 2009-12-22 2016-11-16 赛诺菲巴斯德有限公司 免疫原性组合物和相关的方法
US20130183350A1 (en) * 2009-12-22 2013-07-18 Kevin Harper Immunogenic compositions
GB201003924D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Immunogenic composition
WO2011112717A1 (en) 2010-03-09 2011-09-15 Biomedical Research Models, Inc. A novel mucosal vaccination approach for herpes simplex virus type-2
WO2011110634A1 (en) 2010-03-10 2011-09-15 Glaxosmithkline Biologicals S.A. Vaccine composition
BR112012026227A2 (pt) 2010-04-13 2020-08-04 Celldex Therapeutics, Inc. anticorpo monoclonal humano ou humanizado, molécula biespecífica, vetor de expressão, célula transformada, composição, e, usos de um anticorpo
GB201015132D0 (en) 2010-09-10 2010-10-27 Univ Bristol Vaccine composition
WO2012072769A1 (en) 2010-12-01 2012-06-07 Novartis Ag Pneumococcal rrgb epitopes and clade combinations
GB201022007D0 (en) 2010-12-24 2011-02-02 Imp Innovations Ltd DNA-sensor
WO2012134975A1 (en) 2011-03-28 2012-10-04 St. Jude Children's Research Hospital Methods and compositions employing immunogenic fusion proteins
CA2832307A1 (en) 2011-04-08 2012-10-18 Immune Design Corp. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
EA201391456A1 (ru) 2011-05-17 2014-05-30 Глаксосмитклайн Байолоджикалс С.А. ВАКЦИНА ПРОТИВ Streptococcus pneumoniae
PT2811981T (pt) 2012-02-07 2019-06-12 Infectious Disease Res Inst Formulações adjuvantes melhoradas que compreendem os agonistas de tlr4 e os seus métodos de utilização
CN104519910B (zh) 2012-03-07 2017-05-03 诺华股份有限公司 肺炎链球菌抗原的含佐剂制剂
DK2850431T3 (en) 2012-05-16 2018-07-16 Immune Design Corp Vaccines against HSV-2
WO2014107731A1 (en) 2013-01-07 2014-07-10 Biomedical Research Models, Inc. Therapeutic vaccines for treating herpes simplex virus type 2 infections
ES2685894T3 (es) 2013-03-08 2018-10-15 Pfizer Inc. Polipéptidos de fusión inmunogénicos
CN105209047B (zh) 2013-04-18 2020-08-18 免疫设计股份有限公司 用于癌症治疗的gla单一疗法
WO2014186796A1 (en) 2013-05-17 2014-11-20 The Board Of Regents Of The University Of Texas System Immunization to protect against adverse cardiac events relating to pneumococcal infection
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
CN106163551A (zh) 2013-12-31 2016-11-23 传染性疾病研究院 单瓶疫苗制剂
US9815886B2 (en) 2014-10-28 2017-11-14 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
DK3220937T3 (da) 2014-11-21 2024-12-02 Univ Oklahoma Pneumolysinmutanter og fremgangsmåder til anvendelse deraf
EP3268037B1 (en) 2015-03-09 2022-08-31 Celldex Therapeutics, Inc. Cd27 agonists
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
WO2017176076A1 (en) 2016-04-06 2017-10-12 Ewha University - Industry Collaboration Foundation A peptide with ability to penetrate cell membrane
US20200377606A1 (en) 2016-04-18 2020-12-03 Celldex Therapeutics, Inc. Agonistic antibodies that bind human cd40 and uses thereof
US11266602B2 (en) 2016-05-16 2022-03-08 Infectious Disease Research Institute PEGylated liposomes and methods of use
IL299285B2 (en) 2016-05-16 2024-12-01 Access To Advanced Health Inst Formulation containing tlr agonist and methods of use
JP7140684B2 (ja) 2016-06-01 2022-09-21 アクセス ツー アドバンスト ヘルス インスティチュート サイジング剤含有ナノアラム粒子
GB201610599D0 (en) 2016-06-17 2016-08-03 Glaxosmithkline Biologicals Sa Immunogenic Composition
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
BR112019026615B1 (pt) 2017-06-15 2022-08-02 Infectious Disease Research Institute Carreadores lipídicos nanoestruturados e emulsões estáveis e usos dos mesmos
EP3678695A1 (en) 2017-09-08 2020-07-15 Infectious Disease Research Institute Liposomal formulations comprising saponin and methods of use
AU2019256383A1 (en) 2018-04-17 2020-11-26 Celldex Therapeutics, Inc. Anti-CD27 and anti-PD-L1 antibodies and bispecific constructs
WO2020123444A1 (en) 2018-12-11 2020-06-18 Celldex Therapeutics, Inc. Methods of using cd27 antibodies as conditioning treatment for adoptive cell therapy
EP3894431A2 (en) 2018-12-12 2021-10-20 GlaxoSmithKline Biologicals SA Modified carrier proteins for o-linked glycosylation
MX2021014363A (es) 2019-05-25 2022-02-21 Infectious Disease Res Inst Composicion y metodo para secar por pulverizacion una emulsion de vacuna adyuvante.
EP3900739A1 (en) 2020-04-21 2021-10-27 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Synthetic streptococcus pneumoniae saccharide conjugates to conserved membrane protein
EP3919076A1 (en) 2020-06-02 2021-12-08 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Synthetic oligosaccharide vaccines against streptococcus pneumoniae with microparticle adjuvant formulations
AU2021337493A1 (en) 2020-09-04 2023-05-18 Access To Advanced Health Institute Co-lyophilized rna and nanostructured lipid carrier
BR112023020303A2 (pt) 2021-04-09 2023-11-14 Celldex Therapeutics Inc Anticorpos contra ilt4, anticorpo anti-ilt4/pd-l1 bispecífico e seus usos
WO2023077521A1 (en) 2021-11-08 2023-05-11 Celldex Therapeutics, Inc Anti-ilt4 and anti-pd-1 bispecific constructs
AU2022391752A1 (en) 2021-11-18 2024-06-13 Matrivax, Inc. Immunogenic fusion protein compositions and methods of use thereof
WO2024052882A1 (en) 2022-09-09 2024-03-14 Access To Advanced Health Institute Immunogenic vaccine composition incorporating a saponin

Also Published As

Publication number Publication date
AU4756490A (en) 1990-07-10
ATE205534T1 (de) 2001-09-15
FI103122B (fi) 1999-04-30
AU626961B2 (en) 1992-08-13
JP3237842B2 (ja) 2001-12-10
DK173629B1 (da) 2001-05-14
EP0449856B1 (en) 2001-09-12
NO912226L (no) 1991-07-25
WO1990006951A1 (en) 1990-06-28
DE68929323T2 (de) 2002-04-18
FI912878A0 (fi) 1991-06-14
NO912226D0 (no) 1991-06-11
FI103122B1 (fi) 1999-04-30
EP0449856A4 (en) 1992-05-20
DK115591A (da) 1991-08-14
RU2121481C1 (ru) 1998-11-10
DK115591D0 (da) 1991-06-14
CA2005704C (en) 2003-02-11
JPH04503948A (ja) 1992-07-16
NO304317B1 (no) 1998-11-30
DE68929323D1 (de) 2001-10-18
CA2005704A1 (en) 1990-06-16
EP0449856A1 (en) 1991-10-09
MC2178A1 (fr) 1992-05-22
HUT58804A (en) 1992-03-30
BG51358A3 (en) 1993-04-15

Similar Documents

Publication Publication Date Title
ES2160570T3 (es) Mutantes de neumolisina y vacunas de neumococos fabricadas a partir de los mismos.
EA199700272A1 (ru) Вакцины, содержащие сапонин и стерин
HK1007330A1 (en) Generation of xenogeneic antibodies
NO822632L (no) Fremgangsmaate for fremstilling av epoksyharpikser med hoeyere molekylvekt, samt fremgangsmaate for fremstilling av harpiksimpregnerte underlag
DK37290D0 (da) Humant immunsystem i ikke-humane dyr
FI891283A (fi) Ifosfamid-mesna-lyofilisat och foerfarande foer dess framstaellning.
ATE105334T1 (de) Schimaerische glykoproteine enthaltende immunogenische abschnitte von menschlichem parainfluenzavirus typ 3.
IT7902502A0 (it) Progetto per la captazione, concentrazione, sfruttamento ed accumulo dell'energia solare.
HUP9701586A2 (hu) Javított inaktivált vakcinák
BG45552A3 (bg) Метод за получаване на 2-фенил-хексахидро-1,2,4- триазин-3,5-диони
IT1167194B (it) Composizione pirotecnica generatrice di fumo opaco all'irraggiamento infrarosso,munizione fumogena ottenuta
ES2059784T3 (es) Derivado antigeno de la estreptolisina o, su produccion y usos.
FR2513122B1 (es)
JPS5696692A (en) Novel influenza virus strain and influenza virus vaccine containing same
DE68917138D1 (de) Toleranzinduktion gegenüber einem fremdantigen.
DE68918649D1 (de) Lebende Newcastle-Krankheit-Virus-Vakzine.
IT8619306A0 (it) Procedimento e composizione per combattere la tignola crociata della vite.
ES2017258A6 (es) Un metodo para producir peptidos antigenicos relacionados con el antigeno p97 asociado a melanoma.
NO881290D0 (no) Mateanlegg.
Kiseleva New and rare plants at foothills of the Eastern Sajan mountain chain, 3.
IT7924482A0 (it) Impianto con serra e camino per lo sfruttamento dell'energia solare.
IT8709303A0 (it) Procedimento per la formazione di un albero artificiale,come un albero di natale,ed albero artificiale cosi' realizzato.
IT8621653A0 (it) Caldaia, particolarmente studiata per la combustione di carboni grassi e semigrassi, provvista di una griglia di attizzamento di tipo perfezionato.
IT8619300A0 (it) Sistema di sorgenti artificiali di energia sismica.
DK616989A (da) Humane monoklonale antistoffer, der specifikt genkender rabiesvirusceller, celler, der prducerer denne virus, formuleringer, der indeholder virusen, samt fremstilling af disse antistoffer

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 449856

Country of ref document: ES